言語を選択

IL-17 RA

IL-17 RA 詳細

英語名	Interleukin-17 receptor A	市販薬剤の数	1
治験薬の数	2	ターゲットの別称	CDw217，IL-17 receptor A，IL17R，IL17RA，Interleukin 17 Receptor A，IL-17RA，Interleukin 17 Receptor，CD217 Antigen，HIL-17R，CANDF5，CD217，IMD51，Interleukin-17 receptor A
研究＆開発段階	Approved

英語名	Interleukin-17 receptor A
ターゲットの別称	CDw217，IL-17 receptor A，IL17R，IL17RA，Interleukin 17 Receptor A，IL-17RA，Interleukin 17 Receptor，CD217 Antigen，HIL-17R，CANDF5，CD217，IMD51，Interleukin-17 receptor A
市販薬剤の数	1
治験薬の数	2
研究＆開発段階	Approved

IL-17 RA 製品リスト

属性
Protein (7)
製品ライブラリ
オンライン (7)
種
Human (4)Cynomolgus (1)Rat (1)Mouse (1)
タグ
His Tag (3)Fc Tag & Avi Tag (1)His Tag & Avi Tag (1)Fc Tag (2)
マーカー
Unconjugated (5)Biotin-labeled (2)

製品番号	種	発現システム	製品説明
HOT ILA-H82F1	Human	HEK293	Biotinylated Human IL-17 RA / CD217 Protein, Fc,Avitag™
ILA-H5222	Human	HEK293	Human IL-17 RA / CD217 Protein, His Tag
ILA-H525f	Human	HEK293	Human IL-17 RA / CD217 Protein, Fc Tag (MALS verified)
ILR-H82E5	Human	HEK293	Biotinylated Human IL-17 RA / CD217 Protein, His,Avitag™
ILA-M52H6	Mouse	HEK293	Mouse IL-17 RA / CD217 Protein, His Tag (MALS verified)
ILA-C52H9	Cynomolgus	HEK293	Cynomolgus IL-17 RA / CD217 Protein, His Tag (MALS verified)
ILA-R5253	Rat	HEK293	Rat IL-17 RA / CD217 Protein, Fc Tag (MALS verified)

総数量7

IL-17 RAバックグランド

Interleukin 17 receptor A (IL17RA) is also known as cluster of differentiation w217 (CDw217), is a pro-inflammatory cytokine secreted by activated T-lymphocytes, belong to ubiquitous type I membrane glycoprotein, and binds with low affinity to interleukin 17A (IL17A). IL 17R mRNA exhibits a broad tissue distribution, and has been detected in virtually all cells and tissues tested . IL 17RA associates with IL 17RC to form a signaling receptor complex for IL 17 and IL 17F . Ligand and IL 17RA ligation promotes T cell activation and the production of IL - 6, G-CSF, SCF, and multiple pro-inflammatory chemokines. Defects in IL17RA are the cause of familial candidiasis type 5 (CANDF5).

IL-17 RA分子の別称

CD217,CDw217,IL-17RA,IL17R,CANDF5,hIL-17R

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
XCUR-17	XCUR-17	Phase 1 Clinical	Exicure Inc	Psoriasis	詳細
PN-881	PN-881	Phase 1 Clinical	Protagonist Therapeutics Inc	Dermatitis; Psoriasis	詳細

市販薬剤に関する情報

英語名	研究コード	研究開発ステージ	会社	オリジナル製品名	最初に承認をした国	最初の適応症	最初に承認を受けた会社	承認された日付	適応症	臨床試験
Brodalumab	AMG-827; KHK-4827; IL-17R mAb; MEDI-6365	Approved	Amgen Inc	Siliq, Lumicef, Kyntheum, 立美芙	Japan	Psoriasis; Arthritis, Psoriatic	Kyowa Kirin Co Ltd	2016-07-04	Arthritis, Psoriatic; Arthritis, Rheumatoid; Asthma; Axial Spondyloarthritis; Brain Neoplasms; Breast Neoplasms; Colonic Neoplasms; Crohn Disease; Esophageal Neoplasms; Genital Neoplasms, Female; Head and Neck Neoplasms; Hidradenitis Suppurativa; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Mouth Neoplasms; Non-radiographic axial spondyloarthritis; Palmoplantar pustulosis; Pancreatic Neoplasms; Plaque psoriasis; Prostatic Neoplasms; Psoriasis; Pustular psoriasis; Rectal Neoplasms; Scleroderma, Systemic; Skin Neoplasms; Solid tumours; Spondylitis, Ankylosing; Stomach Neoplasms; Testicular Neoplasms; Thyroid Neoplasms	詳細